BioCentury | May 26, 2014
Clinical News

Suberohydroxamic acid phenyl ester: Phase Ib data

...has Orphan Drug designation in the U.S. TetraLogic gained the compound through its acquisition of Shape Pharmaceuticals Inc....
BioCentury | Apr 14, 2014
Company News

Shape Pharmaceuticals, TetraLogic deal

...by Healthcare Ventures. TetraLogic declined to disclose financial details, and Shape could not be reached. Shape Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Emerging Company Profile

Syros: Super maps

...on epigenetics and cancer gene regulation in the last five years: Acetylon Pharmaceuticals Inc. , Shape Pharmaceuticals Inc....
...Boston, Mass. Harvard Medical School , Boston, Mass. Massachusetts Institute of Technology (MIT), Cambridge, Mass. Shape Pharmaceuticals Inc....
BioCentury | Oct 11, 2012
Strategy

Leukemia team building

...PI3K) and polo-like kinase 1 (PLK1; STPK13) inhibitor Myelodysplastic syndrome (MDS) Phase III $12.5 M Shape Pharmaceuticals Inc....
BioCentury | Mar 15, 2012
Targets & Mechanisms

Halofuginone target ID

...team is developing topically active compounds that limit systemic exposure. Mazitschek is a cofounder of Shape Pharmaceuticals Inc....
...La Jolla, Calif. Massachusetts General Hospital , Boston, Mass. Promedior Inc. , Malvern, Pa. Shape Pharmaceuticals Inc....
Items per page:
1 - 5 of 5
BioCentury | May 26, 2014
Clinical News

Suberohydroxamic acid phenyl ester: Phase Ib data

...has Orphan Drug designation in the U.S. TetraLogic gained the compound through its acquisition of Shape Pharmaceuticals Inc....
BioCentury | Apr 14, 2014
Company News

Shape Pharmaceuticals, TetraLogic deal

...by Healthcare Ventures. TetraLogic declined to disclose financial details, and Shape could not be reached. Shape Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Emerging Company Profile

Syros: Super maps

...on epigenetics and cancer gene regulation in the last five years: Acetylon Pharmaceuticals Inc. , Shape Pharmaceuticals Inc....
...Boston, Mass. Harvard Medical School , Boston, Mass. Massachusetts Institute of Technology (MIT), Cambridge, Mass. Shape Pharmaceuticals Inc....
BioCentury | Oct 11, 2012
Strategy

Leukemia team building

...PI3K) and polo-like kinase 1 (PLK1; STPK13) inhibitor Myelodysplastic syndrome (MDS) Phase III $12.5 M Shape Pharmaceuticals Inc....
BioCentury | Mar 15, 2012
Targets & Mechanisms

Halofuginone target ID

...team is developing topically active compounds that limit systemic exposure. Mazitschek is a cofounder of Shape Pharmaceuticals Inc....
...La Jolla, Calif. Massachusetts General Hospital , Boston, Mass. Promedior Inc. , Malvern, Pa. Shape Pharmaceuticals Inc....
Items per page:
1 - 5 of 5